HEC-007 / Sunshine Lake Pharma - LARVOL DELTA

A single-centre, randomised, double-blind, placebo-controlled, phase I clinical trial to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of HEC-007 injection in healthy subjects administered as a single dose and in overweight or obese subjects administered as multiple doses (ChiCTR) - P1 | N=126 | Recruiting | Sponsor: The Second Hospital of Anhui Medical University; The Second Hospital of Anhui Medical University

New P1 trial • Diabetes • Genetic Disorders • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus • NFKBIA

A Study to Evaluate the Safety, Tolerability, PK/PD of HEC-007 Injection in Healthy and Overweight/Obese Subjects (clinicaltrials.gov) - P1 | N=126 | Recruiting | Sponsor: Sunshine Lake Pharma Co., Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • Obesity

A Study to Evaluate the Safety, Tolerability, PK/PD of HEC-007 Injection in Healthy and Overweight/Obese Subjects (clinicaltrials.gov) - P1 | N=126 | Not yet recruiting | Sponsor: Sunshine Lake Pharma Co., Ltd.

New P1 trial • Obesity

East Sunshine Pharmaceutical: HEC-007 Injection [Google translation] (PhIRDA) - "HEC-007 Injection, a Class 1 new drug of HEC Pharma, has obtained implicit approval for clinical trials for two indications: type 2 diabetes and overweight or obesity."

New trial • Obesity • Type 2 Diabetes Mellitus